Epothilones and new analogues of the microtubule modulators in taxane-resistant disease (Q57244875)

Expert Opinion on Investigational Drugs

Europe PubMed Central

title

Epothilones and new analogues of the microtubule modulators in taxane-resistant disease (English)

0 references

Charles Swanton

2

0 references

author name string

Michelle Harrison

series ordinal

1

0 references

language of work or name

English

0 references

publication date

25 March 2008

0 references

published in

0 references

volume

17

0 references

issue

4

0 references

page(s)

523-546

0 references

cites work

Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Chromosomal instability, colorectal cancer and taxane resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Mutations of mitotic checkpoint genes in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

On the road to cancer: aneuploidy and the mitotic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Three classes of genes mutated in colorectal cancers with chromosomal instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Chromosomal instability syndrome of total premature chromatid separation with mosaic variegated aneuploidy is defective in mitotic-spindle checkpoint.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Structural basis of Aurora-A activation by TPX2 at the mitotic spindle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Spindle assembly checkpoint defects and chromosomal instability in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Mutation analysis of mitotic checkpoint genes (hBUB1 and hBUBR1) and microsatellite instability in adult T-cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A comparison of signaling activities induced by Taxol and desoxyepothilone B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Do beta-tubulin mutations have a role in resistance to chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.523